November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023 Read more
November 21, 2023 Regulatory InDex Pharmaceuticals discontinues cobitolimod phase III program Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023 Read more
August 22, 2023 Non Regulatory ”Positive results from PK study with cobitolimod” selected as one of the best abstracts for poster presentation at UEGW Read more
August 2, 2023 Regulatory InDex Pharmaceuticals has been granted a new patent in Europe for the commercial formulation of cobitolimod Read more
May 31, 2023 Regulatory InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan Read more
May 24, 2023 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 24, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2023 Read more
April 26, 2023 Non Regulatory Welcome to an InDex Pharmaceuticals business update presentation in Stockholm on May 9, from 13:00 to 15.30 CET Read more
April 19, 2023 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 12, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2022 Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod Read more
January 27, 2023 Regulatory InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod Read more